sulforaphane has been researched along with moclobemide in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (100.00) | 2.80 |
Authors | Studies |
---|---|
Cuadrado, A; Duarte, P; Estrada-Valencia, M; Fernández-Ginés, R; Franco-Gonzalez, JF; Gago, F; García-Yagüe, ÁJ; Herrera-Arozamena, C; Lagartera, L; León, R; López, MG; Michalska, P; Mills, A; Morales-García, JA; Pérez, C; Pérez-Castillo, A; Rodríguez-Franco, MI | 1 |
Duarte, P; Estrada-Valencia, M; Fernández-Mendívil, C; Herrera-Arozamena, C; León, R; Lombardía, J; López, MG; López-Caballero, P; Michalska, P; Morales-García, JA; Pérez, C; Pérez-Castillo, A; Rodríguez-Franco, MI; Sastre, ED; Senar, S | 1 |
2 other study(ies) available for sulforaphane and moclobemide
Article | Year |
---|---|
Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties.
Topics: Animals; Antioxidants; Cell Line, Tumor; CHO Cells; Cricetulus; Humans; Indoles; Kelch-Like ECH-Associated Protein 1; Ligands; Lipoxygenase Inhibitors; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Monoamine Oxidase Inhibitors; Naphthalenes; Neurogenesis; NF-E2-Related Factor 2; Oxadiazoles; Protein Binding; Quinone Reductases; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2 | 2020 |
Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades.
Topics: Antioxidants; Ligands; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidative Stress; Resveratrol | 2022 |